The objective:

A drug for Alzheimer’s.

A capsule formed from purple and translucent white binary digits.
Alzheimer’s drug developmentOne hundred dots hold a scattered formation during the first statement, then form a grid during the second. In the third, ninety-two dots fade while eight remain highlighted. The colors illustrate the historical 8% Phase 2 to Phase 3 advancement rate, not a forecast of Babylon’s pipeline.
Promising ideas. An unforgiving path to patients.
AdvancedDid not advance within the study period
The problem:

Treating
Alzheimer’s
is hard.

What causes Alzheimer’s is unknown. Betting everything on a single thesis is no longer reasonable.

8%advanced from Phase 2 to Phase 3.

Cummings et al., 2014

So hard, that most
drugs will fail.

But a portfolio of bets can be
engineered to
win at Alzheimer’s.

Our process

AI-enabled therapeutics for Alzheimer’s

We believe transformational medicines begin with bolder scientific bets.

  1. Start with
    bold science.

    Pursue high-risk hypotheses with a strong scientific rationale.

  2. AI agents
    find assets.

    Our AI agents work 24/7 to find assets targeting our pathways of interest.

  3. Expert
    diligence.

    Our team rigorously evaluates candidate molecules, supported by BabGPT.

  4. Toward
    human studies.

    Advance promising candidates toward human studies with extreme urgency.

Recursive AI improvement: team diligence feeds back into AI sourcing.

Our AI gives our superheroes
superpowers.

BabGPT

Illustrative BabGPT concept. No research data is shown.

Treating Alzheimer’s
requires The Avengers.

Our team's previous achievements:

50+FDA-approved medicines
210+Clinical candidates
650+Patents
$78BIn total acquisitions
3ACS Med Chem Hall of Famers
  • Sacha Schermerhorn CEO / Founder NSF GRFP recipient. Published in Nature Neuroscience. Research in neuroscience and machine learning. Life mission to treat Alzheimer's.
  • John Macor, PhD Diligence Team (Chemistry) Renowned drug hunter. 4 FDA-approved drugs. Nurtec® (acq. $11.6B). BACE1 inhibitors. 40 years experience. ACS MedChem Hall of Fame.
  • Bill Greenlee, PhD Diligence Team (Chemistry) ACS MedChem Hall of Fame. 3 FDA-approved drugs. Lisinopril: #3 in U.S. prescriptions (2022). Alzheimer’s BACE1 inhibitor verubecestat.
  • Dario Doller, PhD Discovery Team (Chemistry) CNS medicinal chemistry expert. FDA-approved Zontivity®. Multiple clinical brain-disease candidates. Authored multiple leading textbooks.
  • Andy Ambrose, PhD Discovery Team (Chemical Biology) First-in-class molecules for neurodegeneration. Inventor of the first selective Hsp70 chaperone inhibitors. UCSF Arkin Lab alum.
  • Edward Sun Technical Team Roy Vagelos Fellow. Wharton dropout. AI drug discovery research. Former All-State cellist.
  • Juliana McInnis EA to the CEO Former Executive Assistant at KKR, Bechtel, and PagerDuty. Best-in-class positive energy.
  • David Askin, PhD Development Team, CMC Former CMC leader, Genentech and Merck. 7 FDA-approved drugs, including Kadcyla®, Erivedge®, and Januvia®.
  • Richard Libby, PhD Portfolio Team (Risk / Capital) Mathematician and former executive at Bank of America and BGI. Discovered new properties of eigenvalue distributions for Toeplitz operators.
  • Pat Weber, PhD Diligence Team (Structural Biology) Pioneer in structure-based drug design. Victrelis®, narlaprevir, lonafarnib. 100+ papers; 21 issued patents.
  • Eric Parker, PhD Diligence Team (Pharmacology) Former leader at Merck, Schering-Plough, and BMS. Verubecestat, Varubi®. PhRMA award for Alzheimer’s BACE1 research.
  • Yufei Chen Intern 3x Gold medalist at International Olympiads (Bio, Chemistry, Earth Science), Silver (Physics). Perfect SAT score at 12 years old.

Advisors

  • Steve Holtzman Business Development Former EVP, Biogen. Oversaw Alzheimer's partnership with Eisai, leading to Leqembi®. Former CBO, Millennium Pharma (acq. $8.8B).
  • Michelle Arkin, PhD Chemistry Professor at U of Toronto. Protein-protein interactions expert. Xiidra® (acq. $5.3B). Inducted into American Academy of Arts and Sciences.
  • Matt Krisiloff Operations / Fundraising CEO, Conception. Former director, Y Combinator Research. OpenAI founding team. Investor and advisor to 150+ startups.
  • Jason Gestwicki, PhD Drug discovery Interim director, UCSF Institute for Neurodegenerative Diseases. Molecular chaperones. Expert in protein misfolding. AAAS Fellow.

Our investors

The latest.

Scroll to explore

We’ve got more
work to do.

If you want to live in a future without Alzheimer's, we want to hear from you.

“Very intense.” “Unlike any company I've ever worked at.” “Deeply rewarding.” “More motivation to treat Alzheimer's than I've seen in my 40-year career.” “Mission-obsessed.” “We will do this.” “Geniuses.” “Extremely high bar.” “Brings out my best work.” “My dream of playing with Ronaldo and Messi.” “So much fun” “Fastest pace I've ever experienced.” “Those guys are freaks...” “Extremely first-principles.”

Get in touch

Use the left and right arrow keys or scroll sideways to browse team photos.